美多芭单用及联合普拉克索治疗帕金森病的效果评析

Evaluation of the Effect of Medopa Alone and Pramipexole in the Treatment of Parkinson's Disease

目的探讨对帕金森病患者分别采用美多芭以及美多芭+普拉克索药物治疗后获得临床效果。方法将该院2018年6月—2020年4月收治的82例帕金森病患者数字奇偶法分组;联合组(41例):采用美多芭+普拉克索药物展开帕金森病治疗;单一组(41例):采用美多芭药物展开帕金森病治疗。就组间帕金森病疗效数据、各生活质量量表评分以及总用药不良反应率展开对比。结果联合组帕金森病患者用药总疗效数据(95.12%)高于单一组(65.85%),差异有统计学意义(χ^(2)=11.182,P<0.05);治疗前,联合组帕金森病患者心理评分(9.52±1.25)分、生理评分(9.19±1.24)分、独立性评分(9.31±1.71)分、环境评分(9.42±1.72)分以及社会关系评分(9.85±1.69)分同单一组(9.57±1.27)分、(9.22±1.25)分、(9.34±1.73)分、(9.49±1.75)分以及(9.89±1.72)分比较,差异无统计学意义(P>0.05);治疗后,联合组心理评分(14.39±1.39)分、生理评分(14.52±1.42)分、独立性评分(14.62±1.58)分、环境评分(14.69±1.62)分以及社会关系评分(14.55±1.73)分均高于单一组(11.25±1.03)分、(12.02±1.05)分、(11.66±1.09)分、(11.67±1.53)分以及(12.04±1.05)分,差异有统计学意义(t=11.622、9.064、9.874、8.678、7.942,P<0.05);两组帕金森病患者用药不良反应集中于恶心呕吐、头晕、精神症状以及失眠等方面,最终发现联合组帕金森病患者总用药不良反应率(7.32%)低于单一组(24.39%),差异有统计学意义(χ^(2)=4.479,P<0.05)。结论美多芭+普拉克索药物的联合应用,可实现帕金森病患者疗效、生活质量、安全性方面显著增强以及改善,最终可实现帕金森病患者综合状态改善以及有效预后。

Objective To explore the clinical effects obtained after treatment with medopa and medopa+pramipexole in patients with Parkinson's disease.Methods 82 Parkinson’s disease patients admitted to the hospital from June 2018 to April 2020 were divided into groups by digital parity;combined group(41 cases):Parkinson’s disease treatment with medopa+pramipexole;single group(41 cases):Treatment of Parkinson's disease with Madopar.Comparison of the efficacy data of Parkinson's disease between groups,the scores of each quality of life scale,and the total adverse drug reaction rate.Results The total efficacy data of Parkinson's disease patients in the combined group(95.12%)was significantly higher than that of the single group(65.85%),the difference was statistically significant(χ^(2)=11.182,P<0.05));before treatment,the psychological score of Parkinson's disease patients in the combined group was(9.52±1.25)points,physiology score(9.19±1.24)points,Independence score(9.31±1.71)points,environmental score(9.42±1.72)points,and social relationship score(9.85±1.69)points were the same as the single group(9.57±1.27)points,(9.22±1.25)points,(9.34±1.73)points,(9.49±1.75)points and(9.89±1.72)points,the difference was not statistically significant(P>0.05);after treatment,the scores of psychological score(14.39±1.39)points,physiological score(14.52±1.42)points,independence score(14.62±1.58)points,environmental score(14.69±1.62)points and social relationship score(14.55±1.73)points in the combined group were all significantly higher than the single group(11.25±1.03)points,(12.02±1.05)points,(11.66±1.09)points,(11.67±1.53)points and(12.04±1.05)points,the difference was statistically significant(t=11.622,9.064,9.874,8.678,7.942,P<0.05));adverse drug reactions of the two groups of Parkinson's disease patients concentrated on nausea and vomiting,dizziness,mental symptoms,and insomnia.It was finally found that the total adverse drug reaction rate(7.32%)of Parkinson's disease patients in the combined group was lower than that of a single drug group(24.39%),the difference was statistically significant(χ^(2)=4.479,P<0.05).Conclusion The combined application of medopa and pramipexole can achieve significant enhancement and improvement in the efficacy,quality of life,and safety of Parkinson's disease patients,and ultimately can achieve the overall improvement and effective prognosis of Parkinson's disease patients.